News Sanofi outbids J&J for Actelion merger - reports Reports suggest Sanofi could pay $30 billion for Swiss biotech.
News Good news for Amgen as Repatha reverses atherosclerosis Encouraging data could point to strong outcomes data, expected next year
Views & Analysis GSK and Sanofi CEOs: it's drug prices, stupid How pharma can move on from the recent controversies around pricing is one of the industry's biggest issues.
News Pfizer's hopes for cholesterol blockbuster dashed Sales of cancer drug Ibrance also fall short of expectations.
News Sanofi’s dermatitis drug dupilumab fast-tracked by FDA Drug could earn $2.8 billion if approved in AD and asthma
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
